Premium
C‐reactive protein evolution in obstructive sleep apnoea patients under CPAP therapy
Author(s) -
Schiza Sophia E.,
Mermigkis Charalampos,
Panagiotis Panagou,
Bouloukaki Izolde,
Kallergis Eleftherios,
Tzanakis Nikolaos,
Tzortzaki Eleni,
Vlachaki Eleni,
Siafakas Nikolaos M.
Publication year - 2010
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2010.02348.x
Subject(s) - medicine , c reactive protein , surgery , inflammation
Eur J Clin Invest 2010; 40 (11): 968–975 Abstract Background C‐reactive protein (CRP) is recognized as a potential factor implicated in atherogenesis and associated cardiovascular morbidity. The aim of our study was to assess the CRP evolution during 1‐year follow‐up period in obstructive sleep apnoea (OSA) patients under CPAP treatment. Methods Five hundred and twenty‐eight patients with newly diagnosed moderate to severe OSA were included. CRP was assessed before CPAP initiation and at the 3rd, 6th and 12th month of the follow‐up period. Patients were divided into good and poor CPAP compliance groups. Results A significant reduction in CRP levels was observed after CPAP therapy (0·74 ± 0·62 mg dL −1 vs. 0·31 ± 0·29 mg dL −1 , P < 0·001) in the whole patient group. The evolution of CRP values showed a gradual decrease at 3 months with a steep decline at 6 months, reaching a plateau after this time point. When the patients were divided into those with good and poor compliance with CPAP therapy, the above CRP evolution pattern was observed only in the former group. Conclusion Good CPAP compliance results in a significant CRP reduction. To achieve the best positive impact on cardiovascular morbidity and mortality, a time period of at least 6 months of CPAP use is required.